LX4211 significantly reduced A1C to week 12 in a dose-dependent manner by 0.42 % ( 4.6 mmol/mol ) , 0.52 % ( 5.7 mmol/mol ) , 0.80 % ( 8.7 mmol/mol ) , and 0.92 % ( 10.0 mmol/mol ) , respectively ( P < 0.001 each ) , compared with 0.09 % ( 1.0 mmol/mol ) for placebo .